Europäische Union - Deutsch - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kann als monotherapie oder in kombination mit methotrexat verwendet werden. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - baricitinibum - filmtabletten - comprimé pelliculé: baricitinibum 2 mg, mannitolum 52 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - baricitinibum - filmtabletten - comprimé pelliculé: baricitinibum 4 mg, mannitolum 50 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, color.: e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilepsie - antiepileptika, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - tabletten - cenobamatum 12.5 mg, cellulosum microcristallinum, lactosum monohydricum 39.67 mg, carboxymethylamylum natricum a corresp. natrium 0.16 mg, silica colloidalis anhydrica, magnesii stearas, pro compresso. - antieptileptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - filmtabletten - cenobamatum 25 mg, cellulosum microcristallinum, lactosum monohydricum 79.34 mg, carboxymethylamylum natricum a corresp. natrium 0.32 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum, talcum, e 172 (flavum), e 172 (rubrum), e 132, pro compresso obducto. - antieptileptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - filmtabletten - cenobamatum 50 mg, cellulosum microcristallinum, lactosum monohydricum 158.68 mg, carboxymethylamylum natricum a corresp. natrium 0.64 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 4000, talcum, e 172 (flavum), pro compresso obducto. - antieptileptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - filmtabletten - cenobamatum 100 mg, cellulosum microcristallinum, lactosum monohydricum 108.68 mg, carboxymethylamylum natricum a corresp. natrium 0.64 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum, talcum, e 172 (flavum), e 172 (rubrum), e 132, pro compresso obducto. - antieptileptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - filmtabletten - cenobamatum 150 mg, cellulosum microcristallinum, lactosum monohydricum 163.02 mg, carboxymethylamylum natricum a corresp. natrium 0.96 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 4000, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - antieptileptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - filmtabletten - cenobamatum 200 mg, cellulosum microcristallinum, lactosum monohydricum 217.36 mg, carboxymethylamylum natricum a corresp. natrium 1.28 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 4000, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - antieptileptikum - synthetika